12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BIT225: Additional Phase IIa data

Additional data from a double-blind, Thai Phase IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that twice-daily oral BIT225 for 28 days plus standard of care (SOC; peginterferon alfa-2b and ribavirin) led to a complete early virologic response (cEVR) rate, defined as undetectable HCV RNA levels...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >